Therapeutic Targeting Protein Kinase CK2 Ameliorates Lupus Nephritis by Modulating Neutrophil Infiltration and Neutrophil Extracellular Trap Formation
Arthritis & Rheumatology · 02.06.2026
DOI: 10.1002/art.70206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 02.06.2026. Verfasst von Minghua Zhan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of National He…. Die Arbeit nennt 43 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences (CIFMS), National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Objective
Systemic lupus erythematosus (SLE) is a complex autoimmune disease driven by neutrophil dysregulation and neutrophil extracellular trap (NET) formation, with unmet therapeutic needs. This study aimed to investigate the therapeutic potential of protein kinase CK2 inhibitor CX‐4945 in SLE as well as to elucidate the underlying mechanisms.
Methods
CX‐4945 was administered to multiple murine models, including MRL/lpr mice, imiquimod (IMQ)‐induced lupus model, IMQ‐induced psoriasis model, and cecal ligation and puncture–induced sepsis model. Renal function, histopathological changes, immune complex deposition, NET formation, and inflammatory cytokine levels were evaluated.
Results
CX‐4945 significantly ameliorated renal damage in MRL/lpr and IMQ‐induced lupus models, as evidenced by reduced urinary albumin‐to‐creatinine ratio, glomerular abnormalities, immune complex/complement C3 deposition, and neutrophil infiltration. The neutrophils from patients with SLE exhibited elevated CK2α expression and enzyme activity. Mechanistically, CX‐4945 suppressed interferon‐stimulated genes and reactive oxygen species–related pathways, induced mitochondrial metabolic rewiring, inhibited JNK/p38 MAPK phosphorylation, and modified NET protein composition to abrogate macrophage proinflammatory responses.
Conclusion
CK2α is aberrantly up‐regulated in SLE neutrophils, and targeting CK2 with CX‐4945 exerts therapeutic effects in SLE. These findings identify CK2 as a novel therapeutic target for SLE and support the repurposing of CX‐4945 for treating neutrophil‐driven inflammatory and autoimmune diseases. image
Autor:innen und Institutionen
- Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of National Health Commission, Institute of Geriatric Medicine, Chinese Academy of M…
- Department of Clinical Laboratory, Hebei Key Laboratory of Pathogenic Mechanisms and Diagnosis & Treatment Technologies for Lung Microbiome, First Affiliated Hospital of Hebei North University, Zhangjiakou, People's Rep…
- Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Beijing, People's Republic of China.
- National Center for Clinical Laboratories, Institute of Geriatric Medicine, Beijing Hospital/National Center of Gerontology, Peking University Fifth School of Clinical Medicine, Beijing, People's Republic of China.
- Department of Clinical Laboratory, State Key Laboratory of Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's…
- Department of Rheumatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Clinical Immunology Center, Medical School, University of Chinese Academy of Sciences, Beijing, People's Rep…
ORCID-Profile: Minghua Zhan, Honglin Xu, Xuan Zhang, Yudong Liu
Förderung
- CAMS Innovation Fund for Medical Sciences (CIFMS)
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Zhan, M., Dong, S., Bai, Z., Xu, H., Hu, C., Fu, L., Zhang, K., Chen, M., Yuan, Y., Yang, J., Wang, F., Xiao, F., Zhang, X., & Liu, Y. (2026). Therapeutic Targeting Protein Kinase CK2 Ameliorates Lupus Nephritis by Modulating Neutrophil Infiltration and Neutrophil Extracellular Trap Formation. Arthritis & Rheumatology. https://doi.org/10.1002/art.70206
Vancouver
Zhan M, Dong S, Bai Z, Xu H, Hu C, Fu L, et al. Therapeutic Targeting Protein Kinase CK2 Ameliorates Lupus Nephritis by Modulating Neutrophil Infiltration and Neutrophil Extracellular Trap Formation. Arthritis & Rheumatology. 2026. doi:10.1002/art.70206
BibTeX
@article{Zhan2026,
author = {Zhan, Minghua and Dong, Shiran and Bai, Zhou and Xu, Honglin and Hu, Chaotao and Fu, Lufan and Zhang, Ke and Chen, Mei and Yuan, Yulin and Yang, Jinliang and Wang, Fang and Xiao, Fei and Zhang, Xuan and Liu, Yudong},
title = {Therapeutic Targeting Protein Kinase CK2 Ameliorates Lupus Nephritis by Modulating Neutrophil Infiltration and Neutrophil Extracellular Trap Formation},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.70206}
}
EUVIMED